Triple-negative breast cancer: trials for referral
480 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Triple-negative breast cancer·What we know·Glossary·Tumour board sheet
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
400 trials shown · Showing the 400 most recently updated of 480 open trials.
Phase 3285 sites
RecruitingArgentina, Australia, Belgium, Brazil, Canada, Chile
NCT06841354
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Merck Sharp & Dohme LLC
Pre-treatment window Registry sentence: “Has received prior systemic therapy for treatment of locally recurrent unresectable or metastatic breast cancer”
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 127 sites
RecruitingSpain, Georgia, United States
NCT07503808
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
IDEAYA Biosciences
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 13 sites
RecruitingSouth Korea
NCT07423117
A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy
IntoCell, Inc
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 3340 sites
RecruitingArgentina, Australia, Belgium, Brazil, Canada, Chile
NCT06966700
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Merck Sharp & Dohme LLC
Pre-treatment window Registry sentence: “Has previously untreated high-risk, early-stage, non-metastatic (M0) breast cancer (BC), defined as any of the following combined primary tumor (T) and regional lymph node (N) staging per AJCC 8th edition criteria as assessed by the physician investigator based on radiological and/or clinical assessment:”
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 14 sites
RecruitingUnited States
NCT07652242
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
Immunomic Therapeutics, Inc.
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 19 sites
RecruitingGermany, Italy
NCT05492682
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Valo Therapeutics Oy
Registry updated 9 Nov 2026 · The registries disagree on the status
Registry record: ClinicalTrials.govPhase 21 site
RecruitingChina
NCT06793332
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
Fudan University
Pre-treatment window Registry sentence: “Ten tissue pathology slides of the primary lesion and/or metastatic lesion (preferably metastatic lesion) can be obtained before the start of treatment for exploratory analysis of molecular indicators related to therapeutic efficacy.”
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 1/23 sites
RecruitingChina
NCT07208149
A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
Shenzhen Majory Biotechnology Co., Ltd.
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 32 sites
RecruitingChina
NCT05999149
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
Fudan University
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 1/254 sites
RecruitingAustralia, Germany, Spain, France, United Kingdom, Israel
NCT03424005
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Hoffmann-La Roche
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 121 sites
RecruitingSouth Korea, United States
NCT06586957
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 119 sites
RecruitingSpain, France, United States
NCT07318805
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Pfizer
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 231 sites
RecruitingChina
NCT07876557
A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
Shanghai Junshi Bioscience Co., Ltd.
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 230 sites
RecruitingUnited States
NCT03606967
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “No prior therapy for metastatic TNBC.”
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 3316 sites
RecruitingArgentina, Austria, Australia, Belgium, Brazil, Canada
NCT06393374
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Merck Sharp & Dohme LLC
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 119 sites
RecruitingUnited States
NCT07029399
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingUnited States
NCT07300475
Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients
Washington University School of Medicine
Pre-treatment window Registry sentence: “Newly diagnosed, previously untreated, locally advanced non-metastatic triple negative breast cancer (as defined by the most recent ASCO/CAP guidelines).”
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingChina
NCT06802757
Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer
Shandong Cancer Hospital and Institute
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingUnited States
NCT07862751
US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Chemotherapy
Emory University
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 112 sites
RecruitingUnited States
NCT06150664
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Compass Therapeutics
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 3375 sites
RecruitingAustralia, Belgium, Brazil, Germany, Spain, France
NCT05633654
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Gilead Sciences
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 139 sites
RecruitingAustralia, China, Spain, France, United Kingdom, Japan
NCT06465069
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Eli Lilly and Company
Pre-treatment window Registry sentence: “Cohort D: Treatment-naive for locally advanced or metastatic urothelial cancer.”
Registry updated 4 Nov 2026 · The registries disagree on the status
Registry record: ClinicalTrials.govPhase 125 sites
RecruitingAustralia, Spain, France, Italy, Japan, South Korea
NCT06400472
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 1/267 sites
RecruitingChina, Japan, South Korea, United States
NCT05579366
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Genmab
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 22 sites
Not yet recruitingUnited States
NCT07914309
Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer
Washington University School of Medicine
Pre-treatment window Registry sentence: “Histologically or cytologically confirmed, untreated, locally advanced, non-metastatic triple-negative breast cancer.”
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT07407920
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
M.D. Anderson Cancer Center
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govEarly Phase 16 sites
RecruitingAustralia
NCT06305962
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
Radiopharm Theranostics, Ltd
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 1/24 sites
RecruitingSpain
NCT05451784
Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS
Fundacio Clinic Barcelona
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 12 sites
RecruitingUnited States
NCT07341867
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Andrew Hantel, MD
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 120 sites
RecruitingUnited Kingdom, United States
NCT06545331
Study of XB010 in Subjects With Solid Tumors
Exelixis
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States159 open trials
- China121 open trials
- France34 open trials
- Spain30 open trials
- Australia27 open trials
- Japan24 open trials
- United Kingdom23 open trials
- Italy22 open trials
- Germany22 open trials
- South Korea22 open trials
- Canada21 open trials
- Belgium13 open trials
- Israel10 open trials
- Poland9 open trials
- Netherlands9 open trials
- Brazil8 open trials
- Taiwan7 open trials
- Argentina6 open trials
- India6 open trials
- Colombia5 open trials
- Denmark5 open trials
- Singapore5 open trials
- Türkiye4 open trials
- Czechia4 open trials
- Chile4 open trials
- Romania4 open trials
- Mexico4 open trials
- Portugal4 open trials
- Thailand3 open trials
- Malaysia3 open trials
- South Africa3 open trials
- Switzerland3 open trials
- Sweden3 open trials
- Austria3 open trials
- Hungary2 open trials
- Ukraine2 open trials
- Hong Kong2 open trials
- New Zealand2 open trials
- Georgia2 open trials
- Vietnam2 open trials
- Ireland2 open trials
- Puerto Rico2 open trials
- Nigeria2 open trials
- Peru1 open trial
- Guatemala1 open trial
- Greece1 open trial
- Norway1 open trial
- Ghana1 open trial
- Jamaica1 open trial
- Barbados1 open trial
- Indonesia1 open trial
- United Arab Emirates1 open trial
- Russia1 open trial
- Belarus1 open trial
- Saudi Arabia1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Cancer Hospital of Chinese Academy of Medical Sciences
Beijing, China
18 trials · 30 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
Status changed: By invitation only → Recruiting
NCT07423117 · Phase 1 · South Korea
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07486687 · Phase 3 · Netherlands
Source: ClinicalTrials.govOpened for recruitment
NCT07318805 · Phase 1 · Spain, France, United States
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07151586 · Phase 2 · France
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07178730 · Phase 3 · Germany, Poland
Source: ClinicalTrials.govOpened for recruitment
NCT06926868 · Phase 2/3 · United Arab Emirates, Argentina, Austria, Australia, Brazil, Canada
Source: ClinicalTrials.govPhase changed: Phase 2/3 → Phase 2
HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011
NCT06369831 · Phase 2 · Austria, Belgium
Source: ClinicalTrials.govClosed for recruitment
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892 · Phase 2 · Australia, Canada, Germany, Spain, France, United Kingdom
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892 · Phase 2 · Australia, Canada, Germany, Spain, France, United Kingdom
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC
NCT05498896 · Phase 2 · Germany, Spain, United Kingdom
Source: ClinicalTrials.govOpened for recruitment
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
NCT05492682 · Phase 1 · Germany, Italy
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
NCT04556773 · Phase 1 · Australia, Belgium, Brazil, Canada, France, South Korea
Source: ClinicalTrials.govOpened for recruitment
NCT04300556 · Phase 1/2 · Spain, France, United Kingdom, Japan, United States
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT03997123 · Phase 3 · Argentina, Brazil, Canada, China, Colombia, Czechia
Source: ClinicalTrials.gov
Show more
Status changed: Completed → Running, not recruiting
NCT03562637 · Phase 3 · Australia, Brazil, China, Hong Kong, South Korea, Mexico
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT06358573 · Phase 2 · Switzerland, France
Source: ClinicalTrials.govClosed for recruitment
NCT06926868 · Phase 2/3 · United Arab Emirates, Argentina, Austria, Australia, Brazil, Canada
Source: ClinicalTrials.govOpened for recruitment
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892 · Phase 2 · Australia, Canada, Germany, Spain, France, United Kingdom
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07318805 · Phase 1 · Spain, France, United States
Source: ClinicalTrials.govClosed for recruitment
NCT04300556 · Phase 1/2 · Spain, France, United Kingdom, Japan, United States
Source: ClinicalTrials.govClosed for recruitment
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
NCT05492682 · Phase 1 · Germany, Italy
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 2Ended 15 Oct 2026
No phaseEnded 10 Aug 2026
Withdrawn before start0 participants
NCT06610097
TNBC Gut Microbiota During Neoadjuvant Treatment
Reason given: no patients were able to be enrolled
Phase 2Ended 5 Aug 2026
Completed78 participants
NCT03414684
Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
Phase 2Ended 31 Jul 2026
Completed184 participants
NCT05445908
SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer
Phase 2Ended 29 Jul 2026
Stopped early20 participants
NCT06568692
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Reason given: Business Reason
Phase 2Ended 23 Jul 2026
Completed100 participants
2024-512082-14-00
Short-term Pre-OPerative Durvalumab (MEDI 4736) in early small triple negative breast cancer patients (POP-Durva)
No phaseEnded 16 Jul 2026
Withdrawn before start0 participants
NCT07226102
Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer
Reason given: slow accrual
No phaseEnded 13 Jul 2026
Completed3648 participants
NCT07820228
Survival Analysis of Early Triple Negative Breast Cancer (TNBC) Women Treated With Dose Dense Sequential Adjuvant Chemotherapy
Phase 1/2Ended 9 Jul 2026
Phase 1Ended 8 Jul 2026
Completed27 participants
NCT06399757
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Phase 2Ended 7 Jul 2026
Completed31 participants
NCT06604858
Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer
Phase 2Ended 1 Jul 2026
Completed36 participants
NCT07827079
A Study of Tislelizumab Combined With TAC Regimen as Neoadjuvant Therapy for TNBC
No phaseEnded 1 Jul 2026
Completed100 participants
NCT07714382
Survival Outcomes of Residual Disease in Triple-Negative Breast Cancer
No phaseEnded 16 Jun 2026
Withdrawn before start0 participants
NCT07136493
Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer
Reason given: Funding This study has been closed at City of Hope at the request of the Sponsor due to delays and changes in study timeline.
Phase 1/2Ended 9 Jun 2026
Stopped early15 participants
NCT04331067
Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Reason given: BMS terminated the study
No phaseEnded May 2026
Withdrawn before start0 participants
NCT04067102
Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC
Reason given: No patients recruited
Phase 2Ended 29 May 2026
Completed65 participants
NCT06685796
A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer
Phase 1/2Ended 8 May 2026
Completed117 participants
NCT05181462
Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.
Phase 2Ended 20 Apr 2026
Phase 1Ended 9 Apr 2026
Stopped early10 participants
NCT06878248
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
Reason given: Business Decision
Show more
Phase 1Ended 17 Mar 2026
Stopped early85 participants
NCT05827614
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
Reason given: Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safety signal.
No phaseEnded 11 Mar 2026
Stopped early3 participants
NCT05742269
Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer
Reason given: Slow patient accrual; decreasing use of IMP.
- Feasibility of [89Zr]Zr-Atezolizumab Immuno-PET for PD-L1 Quantification in the Clinical Work-up of Metastatic Triple-Negative Breast Cancer. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026
Phase 2Ended 10 Mar 2026
Completed29 participants
NCT04877821
The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC
Phase 1Ended 24 Feb 2026
Stopped early7 participants
NCT06351332
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
Reason given: Zentalis terminated contract due to concern for toxicity safety from previously reported serious adverse events. This study had been designed as a Phase I / Phase II study, but never reached Phase II.
Phase 3Ended 5 Feb 2026
Stopped early137 participants
NCT04251533
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
Reason given: The study was terminated following a strategic decision to halt recruitment due to persistently slow enrollment. This decision was not driven by any new or unexpected safety concerns.
Phase 1Ended Jan 2026
Withdrawn before start0 participants
NCT04762901
LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer
Reason given: Funding was terminated.
Phase 1/2Ended 28 Jan 2026
Stopped early260 participants
NCT05325866
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Reason given: Sponsor Decision
Phase 1Ended 31 Dec 2025
Withdrawn before start0 participants
NCT02427581
Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Reason given: Drugs not available
Early Phase 1Ended 29 Dec 2025
Completed35 participants
NCT04674306
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
No phaseEnded 12 Dec 2025
Stopped early31 participants
NCT06505018
Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment
Reason given: The study was terminated prematurely due to insufficient patient recruitment.
Phase 2Ended 9 Dec 2025
Completed1 participant
NCT03383679
START : Study on Androgen Receptor and Triple Negative Breast Cancer
Phase 1Ended 8 Dec 2025
Completed5 participants
NCT06894771
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
Phase 1Ended 3 Dec 2025
Stopped early78 participants
NCT03746431
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Reason given: A strategic decision was made to discontinue the study and prioritize other programs within the portfolio. The study was not discontinued due to safety issues or adverse events related to FPI-1434, FPE-1547, or FPI-1175.
Phase 1/2Ended 27 Nov 2025
Completed17 participants
NCT03709446
Leflunomide in Previously Treated Metastatic Triple Negative Cancers
Phase 1Ended 24 Nov 2025
Completed92 participants
2023-505431-12-00
M1774 (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients with advanced solid tumors
Phase 2Ended 24 Nov 2025
Completed92 participants
NCT01750073
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
Phase 2/3Ended 17 Nov 2025
Completed111 participants
2022-500418-24-00
Olaparib Plus Pembrolizumab Compared to Chemotherapy Plus Pembrolizumab After Initial Treatment With Chemotherapy Plus Pembrolizumab in Triple-Negative Breast Cancer
Phase 2Ended 12 Nov 2025
Completed6 participants
NCT03483012
Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis
- A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis. · Breast cancer research and treatment, 2026
Phase 1/2Ended 7 Nov 2025
Stopped early73 participants
NCT04260802
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Reason given: Business Decision
Phase 2Ended 5 Nov 2025
Completed50 participants
NCT05520723
Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED
Phase 1/2Ended 22 Oct 2025
Completed30 participants
2024-518529-14-00
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Phase 3Ended 14 Oct 2025
Completed1174 participants
NCT03036488
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
- Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study. · Annals of surgical oncology, 2026
- Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup Analysis. · Cancer science, 2026
Phase 1Ended 13 Oct 2025
Phase 3Ended 9 Oct 2025
Completed474 participants
NCT02926196
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab
Phase 2Ended 30 Sept 2025
Stopped early24 participants
NCT03225547
Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
Reason given: side effects (rash)
No phaseEnded 30 Sept 2025
Phase 1Ended 25 Sept 2025
Phase 1Ended 25 Sept 2025
Stopped early12 participants
NCT04315233
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
Reason given: No accrual in one year
Phase 2Ended 22 Sept 2025
Stopped early6 participants
NCT04216472
Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
Reason given: \<75% participation
Phase 1Ended 20 Sept 2025
Paused131 participants
NCT05958199
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
Reason given: Business decision
No phaseEnded 15 Sept 2025
Completed49 participants
NCT03586297
Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer
Phase 1Ended 10 Sept 2025
Phase 2Ended 5 Sept 2025
Completed90 participants
2024-512821-10-00
ABCSG 45: A clinical trial that examines whether the treatment with the medication olaparib in combination with the chemotherapy carboplatin is more effective than treatment with a standard chemotherapy (anthracycline/taxane-based) against a specific type of breast cancer (triple-negative) with a biologic characteristic (homologous recombination deficiency)
Phase 2Ended 2 Sept 2025
Completed454 participants
NCT00861705
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
- Molecular evaluation of residual disease following neoadjuvant chemotherapy in triple-negative breast cancer CALGB 40603 (Alliance). · The Journal of clinical investigation, 2026
- Impact of Neoadjuvant Carboplatin in Early-Stage Triple-Negative Breast Cancer: A Pooled Analysis of the BrighTNess, Cancer and Leukemia Group B 40603 (Alliance), and GeparSixto Clinical Trials. · JCO oncology advances, 2026
No phaseEnded 30 Aug 2025
Withdrawn before start0 participants
NCT04291950
Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women
Reason given: Principal investigator is moving to a new institution. Study is closing.
Phase 1/2Ended 30 Aug 2025
Stopped early14 participants
NCT05451849
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Reason given: No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear signal of robust clinical activity.
Phase 1/2Ended 26 Aug 2025
Completed50 participants
NCT02779855
Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Phase 1/2Ended 18 Aug 2025
Stopped early33 participants
NCT06171789
PRO1107 in Patients With Advanced Solid Tumors
Reason given: Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation
Phase 2Ended 5 Aug 2025
Completed611 participants
NCT05007106
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
Phase 2Ended 5 Aug 2025
Not medical advice. fetched 11 Nov 2026